Shigenori Kadowaki
0000-0001-9923-5309
2 papers found
Refreshing results…
An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)
Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysis
Missing publications? Search for publications with a matching author name.